Par to acquire Edict Pharmaceuticals
Par Pharmaceutical Cos. plans to buy Indian generic drug maker Edict Pharmaceuticals in a cash deal valued at up to $37.6 million. Par said Monday that it expects to finalize the agreement, pending customary conditions and approvals, by the end of the year.